News Headlines Article

FDA reviewing heart risk of Glaxo diabetes drug
Modern Healthcare

The Food and Drug Administration will hold a meeting in June to reassess the safety of GlaxoSmithKline’s former blockbuster drug Avandia, which was severely restricted in 2010 due to concerns about its impact on the heart.

Regulators announced the highly unusual move in a government notice published on Friday. The FDA said it will ask a panel of outside experts to review a new analysis of the key study examining Avandia’s heart risks.